Teva Pharmaceutical Industries Limited (TEVA)

Market Cap	19.60B
Revenue (ttm)	16.62B
Net Income (ttm)	-1.29B
Shares Out	1.15B
EPS (ttm)	-1.14
PE Ratio	n/a
Forward PE	6.64
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,508,516
Open	17.22
Previous Close	16.97
Day's Range	16.97 - 17.31
52-Week Range	12.47 - 22.80
Beta	0.61
Analysts	Strong Buy
Price Target	25.00 (+46.28%)
Earnings Date	Jul 30, 2025

About TEVA

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1901
• Employees: 36,830
• Stock Exchange: NYSE
• Ticker Symbol: TEVA
• Website: https://www.tevapharm.com

Financial Performance

In 2024, Teva Pharmaceutical's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.

Analyst Forecast

According to 8 analysts, the average rating for TEVA stock is "Strong Buy." The 12-month stock price forecast is $25.0, which is an increase of 46.28% from the latest price.

Price Target

$25.0

(46.28% upside)

Analyst Consensus: Strong Buy